ClinicalTrials.gg
CompletedNCT01712490Updated Feb 27, 2026Results posted

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A Phase 3 interventional study of brentuximab vedotin and doxorubicin in Hodgkin Lymphoma, sponsored by Takeda. Completed at 215 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,334
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Enrollment
3rd of 80
1,334 · median 52
Started
2012
with 6 others
Phase 3
8 of 80
2 open now
Registered
18th of 80
by date
Lead sponsor
4 of 80
Takeda

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 3rd largest by enrollment, is one of 7 that started in 2012, is one of 8 in phase 3, and was the 18th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

03

Conditions studied

  • Hodgkin Lymphoma

Keywords

  • Hodgkin Lymphoma
  • Hodgkins Lymphoma
  • Antibody, Monoclonal
  • Antibody-Drug Conjugate
  • Antigens, CD-30
  • Immunotherapy
  • Lymphoma
  • Lymphoma, Classical
  • ECHELON-1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Treatment-naïve participants with Ann Arbor Stage III or IV HL.
  2. confirmed classical Hodgkin Lymphoma (HL) according to the current World Health Organization (WHO) classification.
  3. (ECOG) performance status less than or equal to (\<=) 2.
  4. Bidimensional as documented by radiographic technique per the International Working Group Revised Criteria for Response Assessment for Malignant Lymphoma.

Exclusion criteria

Exclusion Criteria:

  1. Nodular lymphocyte predominant Hodgkin lymphoma.
  2. Cerebral/meningeal disease, including signs and symptoms of progressive multifocalleukoencephalopathy (PML).
  3. Sensory or motor peripheral neuropathy.
  4. Prior chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of first study drug dose.
  5. Known (HIV) positive.
  6. Known surface antigen-positive, or known or suspected active infection.

Please note that there are additional exclusion criteria. The study center will determine if you meet all of the criteria.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,334 participants (actual)

Study arms

  • Experimental
    A + AVD

    A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine (DTIC) 375 mg/m\^2.

    Drug: brentuximab vedotin · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine

  • Active comparator
    ABVD

    ABVD consists of doxorubicin 25 mg/m\^2, bleomycin 10 units per square meter (units/m\^2), vinblastine 6 mg/m\^2, and dacarbazine (DTIC) 375 mg/m\^2.

    Drug: doxorubicin · Drug: bleomycin · Drug: vinblastine · Drug: dacarbazine

Interventions

  • Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.

    Also known as: ADCETRIS®, SGN-35

  • Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

    Also known as: Adriamycin

  • Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

  • Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

  • Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

    Also known as: DTIC

06

What researchers measure

Primary outcomes

  1. Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)

    mPFS was defined as the time from the date of randomization to the date of the first of documentation of progressive disease (PD), death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for Hodgkin lymphoma (HL) after completion of frontline therapy. PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Frontline therapy is the part of standard set of treatments.

    Time frame: Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death. Participants without documented death at the time of analysis were censored at the date last known to be alive.

    Time frame: Baseline until death (approximately up to 4 years)

  2. Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF

    CR rate at the end of randomized regimen per investigator was defined as the percentage of participants who achieved CR at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by IRF. CR was defined as disappearance of all evidence of disease.

    Time frame: Baseline up to end of randomized regimen (approximately 1 year)

  3. Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)

    Time frame: Baseline up to 30 days after last dose of study drug (approximately 1 year)

  4. Number of Participants With Abnormal Clinical Laboratory Values

    Time frame: Baseline up to 30 days after last dose of study drug (approximately 1 year)

  5. Event-free Survival (EFS) Per IRF

    EFS was defined as the time from randomization until any cause of treatment failure: PD, premature discontinuation of randomized treatment for any reason, or death due to any cause, whichever occurs first. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir per IRF.

    Time frame: Baseline until PD or discontinuation of treatment or death, whichever occurs first (approximately up to 4 years)

  6. Disease-free Survival (DFS) Per IRF

    DFS per IRF was defined as the time from CR to disease progression as determined by an IRF or to death from lymphoma or acute toxicity from treatment. CR was defined as disappearance of all evidence of disease.

    Time frame: From CR until PD or death (approximately up to 4 years)

  7. Overall Response Rate (ORR) Per IRF

    ORR per IRF was defined as the percentage of participants who achieved CR or partial remission (PR) at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by an IRF. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: Baseline up to end of randomized regimen (approximately 1 year)

  8. Duration of Response (DOR) Per IRF

    DOR per IRF in participants with response was the time between first documentation of response (PR or CR) and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

    Time frame: From first documented response until PD (approximately 4 years)

  9. Duration of Complete Remission (DOCR) Per IRF

    DOCR per IRF in participants with CR was the time between first documentation of CR and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease.

    Time frame: From first documentation of CR until PD (approximately 4 years)

  10. Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy

    CR was defined as disappearance of all evidence of disease as determined by an IRF.

    Time frame: Baseline up to end of frontline therapy (approximately 4 years)

  11. Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy

    CR rate at the end of frontline therapy per IRF was defined as the percentage of participants who achieved CR at the end of frontline therapy that is after completion of either randomized regimen or alternate frontline therapy as determined by an IRF. CR was defined as disappearance of all evidence of disease.

    Time frame: Baseline up to end of frontline therapy (approximately 4 years)

  12. Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2

    PET negativity rate at Cycle 2 was defined as the percentage of participants with negative Cycle 2 PET results defined as Deauville score less than or equal to (\<=) 3 at Cycle 2. The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans.

    Time frame: Cycle 2 Day 25

  13. A+AVD: Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC) and Total Antibody (TAb)

    Time frame: Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose

  14. A+AVD: Cmax: Maximum Observed Plasma Concentration for Brentuximab Vedotin Monomethyl Auristatin E (MMAE)

    Time frame: Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose

  15. A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb

    Time frame: Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose

  16. A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE

    Time frame: Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose

  17. A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin

    The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.

    Time frame: Baseline up to end of treatment (approximately 1 year)

  18. Change From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT

    EORTC QLQ-C30 included 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. It has 28 questions (4-point scale where 1=not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=very poor \[worst\] to 7= excellent \[best\]). Raw scores were converted into scale scores from 0 to 100. For functional scales and global health status/QOL scale, higher scores show better QOL; for symptom scales, lower scores show better QOL. mPFS was time from date of randomization to date of first of documentation of PD, death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for HL after completion of frontline therapy. PD is any new lesion or increase by \>=50% of previously involved sites from nadir.

    Time frame: Baseline up to end of treatment (approximately 1 year)

07

Results

Posted Nov 27, 2018

Participant flow

Participants took part in the study at 218 investigative sites in Asia Pacific, Europe, Latin America, and North America from 09 November 2012 to the primary completion date of 20 April 2017.

Participant flow — Overall Study
MilestoneA+AVDABVD
Started664670
Treated662659
Completed00
Not completed664670
Withdrew: Ongoing601586
Withdrew: Other1111
Withdrew: Withdrawal by subject3644
Withdrew: Lost to follow-up1629

Outcome measures

PrimaryModified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)

mPFS was defined as the time from the date of randomization to the date of the first of documentation of progressive disease (PD), death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for Hodgkin lymphoma (HL) after completion of frontline therapy. PD was defined as any new lesion or increase by greater than or equal to (\>=) 50 percent (%) of previously involved sites from nadir. Frontline therapy is the part of standard set of treatments.

Time frame:
Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)
Reported as:
Median · months
Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)
monthsA+AVDABVD
Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)NA (48.2 to NA)NA (NA to NA)
Statistical analysis
  • A+AVD vs ABVD · Log Rank · p = 0.035 · Hazard ratio (hr): 0.770 · 95% CI 0.603 to 0.983
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death. Participants without documented death at the time of analysis were censored at the date last known to be alive.

Time frame:
Baseline until death (approximately up to 4 years)
Reported as:
Median · months
Overall Survival (OS)
monthsA+AVDABVD
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • A+AVD vs ABVD · Log Rank · p = 0.199 · Hazard ratio (hr): 0.728 · 95% CI 0.448 to 1.184
SecondaryComplete Remission (CR) Rate at the End of Randomized Regimen Per IRF

CR rate at the end of randomized regimen per investigator was defined as the percentage of participants who achieved CR at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by IRF. CR was defined as disappearance of all evidence of disease.

Time frame:
Baseline up to end of randomized regimen (approximately 1 year)
Reported as:
Number · percentage of participants
Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF
percentage of participantsA+AVDABVD
Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF7370
SecondaryNumber of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Time frame:
Baseline up to 30 days after last dose of study drug (approximately 1 year)
Reported as:
Number · participants
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
participantsA+AVDABVD
TEAE653646
SAE284178
SecondaryNumber of Participants With Abnormal Clinical Laboratory Values
Time frame:
Baseline up to 30 days after last dose of study drug (approximately 1 year)
Reported as:
Number · participants
Number of Participants With Abnormal Clinical Laboratory Values
participantsA+AVDABVD
Number of Participants With Abnormal Clinical Laboratory Values662658
SecondaryEvent-free Survival (EFS) Per IRF

EFS was defined as the time from randomization until any cause of treatment failure: PD, premature discontinuation of randomized treatment for any reason, or death due to any cause, whichever occurs first. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir per IRF.

Time frame:
Baseline until PD or discontinuation of treatment or death, whichever occurs first (approximately up to 4 years)
Reported as:
Median · months
Event-free Survival (EFS) Per IRF
monthsA+AVDABVD
Event-free Survival (EFS) Per IRFNA (43.8 to NA)NA (NA to NA)
SecondaryDisease-free Survival (DFS) Per IRF

DFS per IRF was defined as the time from CR to disease progression as determined by an IRF or to death from lymphoma or acute toxicity from treatment. CR was defined as disappearance of all evidence of disease.

Time frame:
From CR until PD or death (approximately up to 4 years)
Reported as:
Median · months
Disease-free Survival (DFS) Per IRF
monthsA+AVDABVD
Disease-free Survival (DFS) Per IRFNA (42.1 to NA)NA (NA to NA)
SecondaryOverall Response Rate (ORR) Per IRF

ORR per IRF was defined as the percentage of participants who achieved CR or partial remission (PR) at the end of treatment with randomized regimen (ABVD or A+AVD) as determined by an IRF. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
Baseline up to end of randomized regimen (approximately 1 year)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Per IRF
percentage of participantsA+AVDABVD
Overall Response Rate (ORR) Per IRF8683
SecondaryDuration of Response (DOR) Per IRF

DOR per IRF in participants with response was the time between first documentation of response (PR or CR) and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease. PR was defined as regression of measurable disease and no new sites.

Time frame:
From first documented response until PD (approximately 4 years)
Reported as:
Median · months
Duration of Response (DOR) Per IRF
monthsA+AVDABVD
Duration of Response (DOR) Per IRFNA (42.1 to NA)NA (NA to NA)
SecondaryDuration of Complete Remission (DOCR) Per IRF

DOCR per IRF in participants with CR was the time between first documentation of CR and PD as determined by an IRF. PD was defined as any new lesion or increase by \>=50% of previously involved sites from nadir. CR was defined as disappearance of all evidence of disease.

Time frame:
From first documentation of CR until PD (approximately 4 years)
Reported as:
Median · months
Duration of Complete Remission (DOCR) Per IRF
monthsA+AVDABVD
Duration of Complete Remission (DOCR) Per IRFNA (42.1 to NA)NA (NA to NA)
SecondaryPercentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy

CR was defined as disappearance of all evidence of disease as determined by an IRF.

Time frame:
Baseline up to end of frontline therapy (approximately 4 years)
Reported as:
Number · percentage of participants
Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy
percentage of participantsA+AVDABVD
Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy813
SecondaryComplete Remission (CR) Per IRF Rate at the End of Frontline Therapy

CR rate at the end of frontline therapy per IRF was defined as the percentage of participants who achieved CR at the end of frontline therapy that is after completion of either randomized regimen or alternate frontline therapy as determined by an IRF. CR was defined as disappearance of all evidence of disease.

Time frame:
Baseline up to end of frontline therapy (approximately 4 years)
Reported as:
Number · percentage of participants
Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy
percentage of participantsA+AVDABVD
Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy7371
SecondaryPositron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2

PET negativity rate at Cycle 2 was defined as the percentage of participants with negative Cycle 2 PET results defined as Deauville score less than or equal to (\<=) 3 at Cycle 2. The Deauville score according to IRF assessment of response was used to evaluate the results of PET scans.

Time frame:
Cycle 2 Day 25
Reported as:
Number · percentage of participants
Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2
percentage of participantsA+AVDABVD
Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 28986
SecondaryA+AVD: Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC) and Total Antibody (TAb)
Time frame:
Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Geometric mean · microgram per milliliter (microgm/mL)
A+AVD: Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC) and Total Antibody (TAb)
microgram per milliliter (microgm/mL)A+AVD
Cycle 1 Day 1: ADC22.9 ± 6.72
Cycle 3 Day 1: ADC23.6 ± 6.81
Cycle 1 Day 1: TAb22.6 ± 5.48
Cycle 3 Day 1: TAb26.4 ± 6.11
SecondaryA+AVD: Cmax: Maximum Observed Plasma Concentration for Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
Time frame:
Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
A+AVD: Cmax: Maximum Observed Plasma Concentration for Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
nanogram per milliliter (ng/mL)A+AVD
Cycle 1 Day 13.20 ± 2.99
Cycle 3 Day 11.36 ± 0.790
SecondaryA+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb
Time frame:
Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · day*microgram per milliliter (day*ug/mL)
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb
day*microgram per milliliter (day*ug/mL)A+AVD
Cycle 1 Day 1: ADC47.4 ± 12.0
Cycle 1 Day 1: TAb93.0 ± 25.7
SecondaryA+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE
Time frame:
Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Reported as:
Mean · day*nanogram per milliliter (day*ng/mL)
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE
day*nanogram per milliliter (day*ng/mL)A+AVD
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE25.3 ± 19.2
SecondaryA+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin

The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.

Time frame:
Baseline up to end of treatment (approximately 1 year)
Reported as:
Number · participants
A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin
participantsA+AVD
ATA positive109
nATA positive12
SecondaryChange From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT

EORTC QLQ-C30 included 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. It has 28 questions (4-point scale where 1=not at all \[best\] to 4=Very Much \[worst\]) and 2 questions (7-point scale where 1=very poor \[worst\] to 7= excellent \[best\]). Raw scores were converted into scale scores from 0 to 100. For functional scales and global health status/QOL scale, higher scores show better QOL; for symptom scales, lower scores show better QOL. mPFS was time from date of randomization to date of first of documentation of PD, death due to any cause, or for participants who were confirmed non complete responders per IRF, receipt of subsequent anticancer therapy for HL after completion of frontline therapy. PD is any new lesion or increase by \>=50% of previously involved sites from nadir.

Time frame:
Baseline up to end of treatment (approximately 1 year)
Reported as:
Mean · units on scale
Change From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT
units on scaleA+AVDABVD
Baseline: With mPFS event78.15 ± 16.52776.68 ± 18.661
Without mPFS event79.85 ± 16.64879.91 ± 16.218
Change at end of treatment: with mPFS event2.68 ± 15.4348.58 ± 17.848
Change at end of treatment: without mPFS event3.35 ± 17.4176.08 ± 16.141

Adverse events

Collected over TEAEs are adverse events that started after the first dose of study drug and no more than 30 days (approximately 1 year) for a serious adverse event after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A+AVD9/662 (1.4%)284/662 (42.9%)644/662 (97.3%)
ABVD13/659 (2%)178/659 (27%)632/659 (95.9%)
Most frequent serious events
Showing 10 of 245
Most frequent serious events
EventA+AVDABVD
Febrile neutropeniaBlood and lymphatic system disorders114/66243/659
PyrexiaGeneral disorders44/66228/659
NeutropeniaBlood and lymphatic system disorders19/6624/659
PneumoniaInfections and infestations18/66215/659
SepsisInfections and infestations14/6624/659
Abdominal painGastrointestinal disorders14/6624/659
PneumonitisRespiratory, thoracic and mediastinal disorders2/66212/659
VomitingGastrointestinal disorders11/6623/659
ConstipationGastrointestinal disorders11/6626/659
DiarrhoeaGastrointestinal disorders11/6621/659
Most frequent other events
Showing 10 of 51
Most frequent other events
EventA+AVDABVD
NeutropeniaBlood and lymphatic system disorders374/662291/659
NauseaGastrointestinal disorders346/662369/659
ConstipationGastrointestinal disorders273/662239/659
VomitingGastrointestinal disorders212/662183/659
FatigueGeneral disorders209/662211/659
Peripheral sensory neuropathyNervous system disorders189/662111/659
DiarrhoeaGastrointestinal disorders176/662121/659
Neuropathy peripheralNervous system disorders174/66285/659
AlopeciaSkin and subcutaneous tissue disorders173/662146/659
PyrexiaGeneral disorders149/662128/659

Baseline characteristics

The intent-to-treat (ITT) population included all participants randomized to treatment.

Age, Continuous
Age, Continuous(years)A+AVDABVDTotal
Mean38.8 ± 15.8340.2 ± 16.0539.5 ± 15.95
Sex: Female, Male
Sex: Female, Male(Participants)A+AVDABVDTotal
Female286272558
Male378398776
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A+AVDABVDTotal
Hispanic or Latino5155106
Not Hispanic or Latino5715771148
Unknown or Not Reported423880
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A+AVDABVDTotal
American Indian or Alaska Native000
Asian5657113
Native Hawaiian or Other Pacific Islander000
Black or African American202545
White5605541114
More than one race181735
Unknown or Not Reported101727
08

Study locations

215 sites
  • Birmingham, Alabama, United States
  • Gilbert, Arizona, United States
  • Tucson, Arizona, United States
  • Burbank, California, United States
  • Duarte, California, United States
  • Fresno, California, United States
  • Fullerton, California, United States
  • La Jolla, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • San Luis Obispo, California, United States
  • Santa Barbara, California, United States
  • Santa Monica, California, United States
  • Stanford, California, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Lonetree, Colorado, United States
  • Washington D.C., District of Columbia, United States
  • Fort Myers, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Lawrenceville, Georgia, United States
  • Chicago, Illinois, United States
  • Maywood, Illinois, United States
  • Niles, Illinois, United States
  • Zion, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Goshen, Indiana, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa, United States
  • Fairway, Kansas, United States
  • Baltimore, Maryland, United States
  • Bethesda, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Rochester, Minnesota, United States
  • Springfield, Missouri, United States
  • St Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Basking Ridge, New Jersey, United States
  • Hackensack, New Jersey, United States
  • Morristown, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Commack, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Rockville Centre, New York, United States
  • The Bronx, New York, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Greenville, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Knoxville, Tennessee, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Tyler, Texas, United States
  • Salt Lake City, Utah, United States
  • Fairfax, Virginia, United States
  • Richmond, Virginia, United States
  • Kennewick, Washington, United States
  • Seattle, Washington, United States
  • Vancouver, Washington, United States
  • Yakima, Washington, United States
  • Morgantown, West Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Kingswood, New South Wales, Australia
  • St Leonards, New South Wales, Australia
  • Westmead, New South Wales, Australia
  • South Brisbane, Queensland, Australia
  • Bedford Park, South Australia, Australia
  • Hobart, Tasmania, Australia
  • East Melbourne, Victoria, Australia
  • Geelong, Victoria, Australia
  • Heidelberg, Victoria, Australia
  • Parkville, Victoria, Australia
  • Perth, Western Australia, Australia
  • Antwerp, Belgium
  • Bruges, Belgium
  • Ghent, Belgium
  • Salvador, Estado de Bahia, Brazil
  • Curitiba, Paraná, Brazil
  • Porto Alegre, Rio Grande do Sul, Brazil

Showing the first 100 of 215 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3. PubMed 40135712 ↗
  • Crosswell HE, LaCasce AS, Bartlett NL, Straus DJ, Savage KJ, Zinzani PL, Collins GP, Fanale M, Fenton K, Dong C, Miao H, Grigg AP. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica. 2024 Mar 1;109(3):982-987. doi: 10.3324/haematol.2023.283303. No abstract available. PubMed 37794803 ↗
  • Ansell SM, Radford J, Connors JM, Dlugosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125. Epub 2022 Jul 13. PubMed 35830649 ↗
  • Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Older patients (aged >/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 May 1;107(5):1086-1094. doi: 10.3324/haematol.2021.278438. PubMed 34162178 ↗
  • Straus DJ, Dlugosz-Danecka M, Connors JM, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Munoz J, Lee HJ, Kim WS, Advani R, Ansell SM, Younes A, Gallamini A, Liu R, Little M, Fenton K, Fanale M, Radford J. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021 Jun;8(6):e410-e421. doi: 10.1016/S2352-3026(21)00102-2. PubMed 34048680 ↗
  • Straus DJ, Dlugosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127. PubMed 31945149 ↗
  • Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7. PubMed 30617130 ↗
  • Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. PubMed 29224502 ↗
  • Younes A, Connors JM, Park SI, Fanale M, O'Meara MM, Hunder NN, Huebner D, Ansell SM. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15. PubMed 24239220 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Apr 2017, 53 months.

Results were first posted in Nov 2018, 1 year 7 months after primary completion.

Of 33 phase 3 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 108. This study's 53 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2012
First posted
Oct 23, 2012
StartActual
Nov 9, 2012
Primary completionActual
Apr 20, 2017
CompletionActual
Feb 2, 2026
Results first posted
Nov 27, 2018
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01712490
Lead sponsor
Takeda
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 23, 2012
Start date
Nov 9, 2012
Primary completion
Apr 20, 2017
Completion
Feb 2, 2026
Results posted
Nov 27, 2018
Last update
Feb 27, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion